The first patient has been dosed in an open-label Phase 1/2 clinical trial of AMT-162, uniQure's one-time gene therapy for SOD1-ALS.| ALS News Today
The European Commission has approved Qalsody to treat ALS patients in the EU whose disease is associated with mutations in the SOD1 gene.| ALS News Today